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ADAM-mediated meprin b shedding is
required for mucus detachment,
regulating intestinal integrity. This work
by Wichert et al. demonstrates that
meprin b is exclusively shed in its pro-
form. Activation of meprin b by the serine
protease MT-2 or the bacterial virulence
factor RgpB abrogates its shedding,
resulting in a disturbed mucus barrier.
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The host metalloprotease meprin b is required for
mucin 2 (MUC2) cleavage, which drives intestinal
mucus detachment and prevents bacterial over-
growth. To gain access to the cleavage site in
MUC2, meprin b must be proteolytically shed from
epithelial cells. Hence, regulation of meprin b shed-
ding and activation is important for physiological
and pathophysiological conditions. Here, we demon-
strate that meprin b activation and shedding are
mutually exclusive events. Employing ex vivo small
intestinal organoid and cell culture experiments, we
found that ADAM-mediated shedding is restricted
to the inactive pro-form of meprin b and is
completely inhibited upon its conversion to the
active form at the cell surface. This strict regulation
of meprin b activity can be overridden by pathogens,
as demonstrated for the bacterial protease Arg-
gingipain (RgpB). This secreted cysteine protease
potently converts membrane-bound meprin b into
its active form, impairing meprin b shedding and its
function as a mucus-detaching protease.
INTRODUCTION
The metalloprotease meprin b is a type 1 transmembrane pro-
tein belonging to the astacin family of zinc endopeptidases2090 Cell Reports 21, 2090–2103, November 21, 2017 ª 2017 The A
This is an open access article under the CC BY license (http://creative(Dumermuth et al., 1991; Sterchi et al., 2008). Meprin b is
highly expressed in epithelial cells of the small intestine (Ster-
chi et al., 1982, 1988), and its role in intestinal homeostasis
and associated diseases such as inflammatory bowel disease
(IBD) has been extensively studied. In the small intestine,
meprin b is responsible for mucin 2 (MUC2) cleavage, which
regulates mucus detachment, important for proper barrier
function (Sch€utte et al., 2014). By contrast, meprin b-deficient
mice are protected against dextran sulfate sodium (DSS)-
induced colitis (Banerjee et al., 2011) because of the loss
of the pro-inflammatory cytokine interleukin-18 (IL-18), which
is a proposed meprin b substrate (Banerjee and Bond,
2008). Thus, meprin b has important but divergent roles in
intestinal homeostasis and in intestinal inflammation, sug-
gesting that meprin b activity must be strictly regulated in
the intestine.
Meprin b is expressed as a zymogen and requires activation by
serine proteases to remove its inhibitory propeptide (Gr€unberg
et al., 1993; Johnson and Bond, 1997; Bode et al., 1992).
Recently, we identified the transmembrane serine protease ma-
triptase-2 (MT-2) as a specific activator of meprin b at the cell
surface (Ja¨ckle et al., 2015). In addition to proteolytic removal
of the inhibitory propeptide, meprin b undergoes ectodomain
shedding from the cell surface by a disintegrin and metallopro-
tease (ADAM) 10 and 17 (Hahn et al., 2003; Jefferson et al.,
2013; Herzog et al., 2014). Importantly, the substrate specificity
of meprin b is dependent on whether meprin b is membrane-
bound or shed into the extracellular space. The recently identi-
fied substrate MUC2 can only be cleaved by soluble meprin b,
which requires meprin b shedding from the cell surface ofuthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Only Inactive Pro-meprin b Is Shed by ADAM10 and ADAM17
(A) Soluble meprin b levels after co-expression of ADAM10/17 or MT-2 and meprin b in HEK293T cells were detected by immunoblotting.
(B) Densitometric analysis of shed meprin b from three biological replicates as shown in (A).
(C) Meprin b activity was measured using a quenched fluorogenic peptide-based assay. mca, (7-methyloxycoumarin-4-yl) acetyl; dnp, 2,4-dinitrophenyl.
(D) Meprin b activity in small intestinal tissue lysates of WT and Mep1b/ mice (n = 3).
(E) Cell surface activity of meprin b on HEK293T cells upon co-transfection with MT-2.
(F) No meprin b activity was detected in cell supernatants of transfected HEK293T cells.
(G) Meprin b activity was increased in trypsin-activated supernatants. Data are presented as mean ± SD, and statistical analysis was assessed by unpaired
Student’s t test (D,E) or one-way ANOVA followed by Dunnett’s test (B,G) from three biological replicates (*p < 0.05, **p < 0.01, ***p < 0.001).
(H) Model of activation and shedding of meprin b.
(I) Orientation of dimeric meprin b based on the crystal structure (PDB: 4GWM). ADAM-mediated pro-meprin b shedding appears N-terminal of the EGF-like
region. Higher magnification of the meprin b activation site shows Arg61 in close proximity to the plasma membrane. Ribbon structure of the catalytic domain is
displayed in blue and the propeptide is shown in red. Arg61 residue at the scissile bond is highlighted as a ball-stick-model in orange.
See also Figure S1.epithelial cells in the small intestine (Sch€utte et al., 2014). MUC2
is secreted from goblet cells and represents the main structural
component of the intestinal mucus layer required for protecting
the host epithelium from bacteria (van Klinken et al., 1999;
Johansson et al., 2008). In the presence of meprin b, the mucus
layer is only loosely attached in the small intestine, leading to
mucus detachment and fast mucus renewal, requiring intestinal
peristalsis. In contrast, the mucus layer of meprin b-deficient
mice is densely packed and tightly attached to the epithelium
(Sch€utte et al., 2014).
To elucidate the regulation and function of meprin b in the
small intestine and its role as a putative therapeutic agent to
target intestinal disorders, we aimed to identify the molecular
features that determine ADAM-mediated shedding. We found
that only inactive pro-meprin b can be shed from the cell
surface, whereas MT-2 binding and activation of mem-
brane-bound meprin b completely prevent ADAM-mediated
shedding. This unique molecular mechanism of enzyme regula-
tion is exploited by the pathogen P. gingivalis, secreting a pro-
tease that is capable of activating the membrane-bound host
metalloprotease meprin b, preventing its shedding, which
would consequently impair its function as a mucus-detaching
protease.RESULTS
ADAM-Mediated Shedding of Meprin b Is Restricted to
Its Inactive Pro-form and Is Completely Prevented after
Its Activation by MT-2
To analyze shedding and activation of membrane-bound
meprin b, HEK293T cells were co-transfected with meprin b
and its sheddases ADAM10/17 or its activator MT-2, respec-
tively (Figure 1A). Increased amounts of soluble meprin b were
detected in the supernatants of ADAM10/17 co-expressing cells,
indicating constitutive shedding of meprin b by those proteases
(Figures 1A and 1B). A small amount of shedmeprin bwas visible
in the supernatant of meprin b single-transfected cells, which
was probably generated by endogenous ADAM activity (Fig-
ure 1A). By contrast, these constitutive levels of soluble meprin
b were strongly reduced after MT-2 co-expression (Figures 1A
and 1B). To determine the proteolytic activity of shed and mem-
brane-bound meprin b, a highly specific quenched fluorogenic
peptide substrate was used (Broder and Becker-Pauly, 2013;
Figure 1C). The specificity of the fluorogenic peptide substrate
was confirmed using small intestinal tissue lysates of meprin
b-deficient mice and corresponding wild-type (WT) animals (Fig-
ure 1D). Although co-expression of MT-2 with meprin b resultedCell Reports 21, 2090–2103, November 21, 2017 2091
Figure 2. Loss of the Sheddase Activity of ADAM10/17 Leads to Secretion of Meprin b by Microvesicles
(A) Meprin b-transfected HEK293T cells were stimulated with 1 mM IM and additionally treated with 3 mM hydroxamate inhibitors GI or GW. Accumulated shed
meprin b was detected in cell supernatants of IM-stimulated cells by immunoblotting. An additional signal for full-length meprin b appeared in supernatants of
GI- or GW-treated cells (*).
(B) Densitometric analysis of shed meprin b from three biological replicates as shown in (A).
(C) Meprin b-transfected HEK293T cells were stimulated with 100 nM PMA and additionally treated with GI or GW. Accumulated shed meprin b was detected in
cell supernatants of PMA-stimulated cells by immunoblotting. An additional signal for full-length meprin b appeared in supernatants of GI- or GW-treated cells (*).
(D) Densitometric analysis of shed meprin b from three biological replicates as shown in (C). Data are presented as mean ± SD, and statistical analysis was
assessed by one-way ANOVA followed by Dunnett’s test (***p < 0.001).
(E) Co-expression of C-terminal FLAG-taggedmeprin b and ADAM10/17 in HEK293T and ADAM10/17/HEK293T cells (CRISPR/Cas). Full-lengthmeprin bwas
detected in cell supernatants using a FLAG3 antibody (*). CTF, C-terminal fragment.
See also Figure S2.in strong activation of meprin b at the cell surface (Figure 1E), no
meprin b activity was detected in cell supernatants from any
treatment condition (Figure 1F) even though soluble meprin b
was readily detected by immunoblotting upon co-transfection
with ADAM proteases (Figure 1A). Because MT-2 co-expression
completely prevented constitutive meprin b shedding (Figures
1A and 1B), we hypothesized that meprin b is shed solely in its
inactive pro-form by ADAM10/17. Indeed, upon pre-incubation
of cell supernatants with recombinant trypsin to activate soluble
meprin b, we observed increased proteolytic activity in superna-
tants of ADAM10/17-co-transfected cells (Figure 1G). However,
nomeprin b activity was detected in the trypsin-activated cell su-
pernatant of MT-2-co-expressing cells (Figure 1G). These results
indicate that ADAM10/17-mediated shedding of meprin b is
restricted to its inactive pro-form and that meprin b shedding is
completely prevented after its activation by MT-2 (Figure 1H),2092 Cell Reports 21, 2090–2103, November 21, 2017despite the fact that known activation and shedding sites are
located differently in the meprin b molecule (Figure 1I). We
confirmed these results with either ionomycin (IM) or phorbol
12-myristate 13-acetate (PMA) stimulation to induce endoge-
nous ADAM10 or ADAM17 activity, respectively (Figure S1).
To determine the specificity of pro-meprin b shedding by
endogenous ADAMs, hydroxamate inhibitors (GI254023X [GI]
for ADAM10 and GW280264X [GW] for ADAM10/17) were used
(Ludwig et al., 2005; Hundhausen et al., 2003). IM induced shed-
ding of pro-meprin b by ADAM10was completely abolished after
addition of the inhibitors GI or GW (Figures 2A and 2B), whereas
PMA-induced ADAM17-mediated shedding of pro-meprin bwas
fully inhibited by GW alone (Figures 2C and 2D). Interestingly, GI
treatment also decreased meprin b shedding in PMA-stimulated
cells, suggesting that ADAM10 plays a crucial role in constitutive
pro-meprin b shedding within HEK293T cells. Again, meprin b
(legend on next page)
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activity in supernatants could only be measured upon trypsin
activation and was significantly decreased in supernatants of
GI- or GW-treated cells (Figures S2A–S2D). Taken together,
these results clearly demonstrate that ADAM10/17 and MT-2
processing of membrane-bound pro-meprin b are mutually
exclusive events and that previous activation of membrane-
bound meprin b by MT-2 completely prevents its shedding by
ADAM10/17.
Inhibition or Knockout of ADAM10/17 Leads to Meprin b
Secretion by Microvesicles
During analysis of meprin b shedding from IM- and PMA-stimu-
lated HEK293T cells, an additional band formeprin bmigrating at
a higher molecular weight (*) appeared after inhibition of ADAMs
by GI or GW (Figures 2A and 2C). To investigate the origin of this
meprin b isoform, we co-expressed C-terminal FLAG-tagged
meprin b and ADAM10/17 in HEK293T cells and in ADAM10/
17/ HEK293T cells (CRISPR/Cas) (Riethmueller et al., 2016).
Interestingly, full-length meprin b was detected in the superna-
tant of ADAM10/17/ cells using a FLAG3 antibody that recog-
nizes the C terminus of membrane-bound meprin b (Figure 2E).
This signal appeared at the same apparent molecular weight
as observed upon inhibition of ADAM10/17 by GI or GW (Figures
2A and 2C). Of note, the signal decreased after re-transfection
with ADAM10/17, whereas meprin b C-terminal fragments
(CTFs) increased again (Figure 2E). However, after ultracentrifu-
gation of cell supernatants, no signal for full-length meprin bwas
detected in western blots using the FLAG3 antibody, and soluble
meprin b was only visible in the presence of its sheddases
ADAM10/17 (Figure 2E). Hence, membrane-bound meprin b is
released into the supernatant via microvesicles in the absence
of its sheddases ADAM10/17. These results indicate that no
other constitutive sheddase for pro-meprin b beside ADAM10/
17 is present in HEK293T cells.
ADAM10 Is the Constitutive Sheddase of Endogenous
Human Pro-meprin b
To identify the constitutive sheddase of pro-meprin b in human
intestinal cells, endogenous meprin b shedding was analyzed
in human colon carcinoma cells (Colo320) after stimulation with
either IM or PMA. Compared with the respective DMSO control
levels, IM stimulation induced a significant increase in shed
pro-meprin b in cell supernatants, which was not the case forFigure 3. ADAM10 Is the Major Sheddase of Endogenous Pro-meprin
(A) Colo320 cells were stimulated with 1 mM IM for 30min or with 100 nMPMA for 2
cell supernatants by immunoblotting.
(B) Densitometric analysis of shed meprin b from three biological replicates as sh
(C) Quantification of meprin b activity in cell supernatants (trypsin-activated) from
analysis was assessed by unpaired Student’s t test (*p < 0.05, **p < 0.01).
(D) Meprin b activity in trypsin activated cell supernatants was inhibited using t
replicates.
(E) The ADAM inhibitor GI or GW was added to cell supernatants of IM- or PMA-
blotting. After inhibition of pro-meprin b shedding, a higher-molecular-weight for
(F) Pre-incubation with GI or GW reduced meprin b activity in trypsin-activated
technical replicates.
(G) Model of pro-meprin b shedding in Colo320 cells.
(H) Quantification of endogenous meprin b activity in supernatants of a primary hu
three biological replicates, and statistical analysis was assessed by unpaired Stu
2094 Cell Reports 21, 2090–2103, November 21, 2017PMA stimulation (Figures 3A and 3B). After trypsin activation,
however, a marked increase in the activity of soluble meprin b
was detected in the cell supernatants of IM-stimulated and, to
a lesser extent, PMA-stimulated cells (Figure 3C), which was
blocked using the meprin inhibitor actinonin (Figure 3D). Further-
more, IM as well as PMA stimulation were both sensitive to GI
inhibition (Figures 3E and 3F). A slight PMA-stimulating effect
on ADAM10 activity has been observed previously (Jefferson
et al., 2013; Maretzky et al., 2005). The ability of the ADAM10-
selective inhibitor GI to block IM- and PMA-stimulated shedding
indicates that ADAM10 is the major sheddase responsible for
endogenous pro-meprin b shedding in Colo320 cells (Figure 3E).
Moreover, trypsin activated meprin b activity in cell superna-
tants, and, thus, pro-meprin b shedding was reduced after pre-
treatment with GI and GW even below control levels, indicating
that constitutive ADAM10 activity was blocked (Figure 3F). In
addition, full-length pro-meprin b (*) was released into the super-
natant via microvesicles after ADAM10 inhibition, indicating
the absence of compensatory meprin b sheddases in Colo320
cells, as previously observed for HEK293T cells (Figures 3E
and 3G). These results clearly indicate that ADAM10 is the critical
sheddase required for endogenous pro-meprin b shedding in
Colo320 cells.
We next analyzed cell supernatants of a primary human in vitro
transwell-like model of the small intestine (Schweinlin et al.,
2016). Here, meprin b activity was measured in cell superna-
tants, which could be significantly increased after trypsin treat-
ment (Figure 3H), indicating that endogenous levels of shed
meprin b were predominantly found in its inactive pro-form.
Shedding and Activation of Membrane-Bound Meprin b
Is Dependent on a Motif N-terminal of the Epidermal
Growth Factor-like Domain
To elucidate the underlying molecular mechanisms for mutually
exclusive proteolytic events ofmeprin b shedding and activation,
we generated a meprin b propeptide variant in which the MT-2
activation site was mutated from arginine residue 61 to a serine
residue (R61S) (Ja¨ckle et al., 2015). Because activation of
membrane-bound meprin b by MT-2 completely prevents its
shedding by ADAM10/17, we hypothesized that Arg61 might
be a competitive recognition motif for both proteases. However,
no differences in ADAM-mediated shedding of the pro-meprin b
variant R61S were detected (Figure 4A), even though nob in Colo320 Cells
hr to induce ADAM10/17 activity, respectively. Shedmeprin bwas detected in
own in (A).
three biological replicates. Data are presented as mean ± SD, and statistical
he meprin inhibitor actinonin (10 mM). SD was calculated from two technical
treated Colo320 cells, and pro-meprin b shedding was analyzed by immuno-
m of meprin b was released into the supernatant (*).
cell supernatants of stimulated Colo320 cells. SD was calculated from two
man small intestinal cell culture model. Data are presented as mean ± SD from
dent’s t test (*p < 0.05).
Figure 4. Binding of Proteolytically Inactive MT-2 to Membrane-Bound Meprin b Shields Meprin b from ADAM Interaction
(A) HEK293T cells were co-transfected with the meprin b propeptide variant R61S and ADAM10/17 or MT-2, respectively. Proteins were analyzed by
immunoblotting.
(B) No increase in cell surface activity of meprin b could be measured after co-expressing meprin b R61S and MT-2. SD was calculated from two technical
replicates.
(C) HEK293T cells were co-transfected with meprin b and ADAM10/17 or the inactive MT-2 variant S753A. Proteins were analyzed by immunoblotting.
(D) No increase in meprin b cell surface activity could be measured in MT-2 S753A co-expressing cells.
(E) No meprin b activity was measured in trypsin-treated cell supernatants of MT-2 S753A co-expressing cells. SD was calculated from two technical replicates.
(F) C-terminal FLAG-tagged meprin b was co-transfected with MT-2 or MT-2 S753A in HEK293T cells and immunoprecipitated for meprin b using a
FLAG3-antibody. Co-immunoprecipitation of MT-2 was detected by immunoblotting.
(G) MT-2 or its inactive variant S753A were co-transfected with meprin b in HEK293T cells and immunoprecipitated for MT-2 using a myc antibody.
Co-immunoprecipitation of meprin b was detected by immunoblotting.activation of meprin b R61S by MT-2 was measured in the cell
surface activity assay (Figure 4B). Importantly, ADAM-mediated
shedding of pro-meprin b R61S in MT-2 co-expressing
cells was prevented to a similar extent as observed for WT
meprin b, indicating a strong non-proteolytic interaction between
MT-2 and membrane-bound meprin b. Upon co-transfection
of HEK293T cells with meprin b and the inactive MT-2 variant
S753A (Figure 4C), shedding of pro-meprin b by ADAM10/17
was prevented to the same extent as observed for active
MT-2 despite no appreciable activation of membrane-bound
meprin b (Figure 4D, E). Accordingly, co-immunoprecipitation
studies demonstrated strong interactions of meprin b with both
active and inactive MT-2 variants (Figures 4F and 4G), which
shields meprin b from any ADAM interaction.
To further investigate the binding exclusivity of MT-2 and
ADAM10/17 to membrane-bound meprin b, we generated ameprin b chimera in which the previously reported ADAM17
cleavage site in human meprin b (hMeprin b) N-terminal of the
epidermal growth factor (EGF)-like domain (Hahn et al., 2003)
was exchanged with the corresponding sequence from murine
meprin b (mMeprin b) (Figure S3A). Shedding and activation of
chimeric meprin b was assessed upon co-transfection with
ADAM10/17 orMT-2 in HEK293T cells (Figure S3B). In the super-
natant of single transfected HEK293T cells, the same molecular
weight shift for chimeric meprin b (*) was detected, as previously
observed in ADAM10/17/ HEK293T cells, indicating impaired
shedding of chimeric meprin b and release of the full-length pro-
tein via microvesicles. Here, only co-transfection with ADAM17,
and not ADAM10, resulted in shedding of chimeric meprin b (Fig-
ure S3B). Surprisingly, chimeric meprin b could not be activated
by MT-2 even though the identified MT-2 cleavage site at posi-
tion Arg61 was not altered (Figure S3C). However, activation ofCell Reports 21, 2090–2103, November 21, 2017 2095
Figure 5. Mucus Attachment in Mouse Ileum Is Dependent on Functional Meprin b
(A–C) Ilea of (A)Mep1b/, (B) tamoxifen (TX)-inducible VilCreER;Adam10f/f, and (C) VilCre;Adam17f/f mice were stained for meprin b (red) and mucin 2 (MUC2,
green) and visualized by immunofluorescence microscopy. Scale bars, 20 mm. Meprin b-deficient mice (A, n = 3) and ADAM10-deficient mice (B, n = 4) showed
strong accumulation of MUC2, which was not seen in VilCre;Adam17f/f animals (C, n = 3). Data are presented asmean ±SD, and statistical analysis was assessed
by unpaired Student’s t test (*p < 0.05, **p < 0.01).
(legend continued on next page)
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chimeric meprin b was not generally abolished because trypsin
activated chimeric meprin b as efficiently as WT hMeprin b (Fig-
ure S3D). These results suggest that the motif N-terminal of the
EGF-like domain of hMeprin b is important for interaction with
ADAM10 and MT-2, thus explaining the mutually exclusive bind-
ing of both proteins to membrane-bound hMeprin b.
Meprin b Shedding and Activation Are Regulated by
Host-Microbiome Interaction
To investigate the role of ADAM-mediated pro-meprin b shed-
ding and its effect on mucus detachment in vivo, we studied
ADAM10/17-deficient mice. Because meprin b-deficiency as
well as the lack of shed meprin b in germ-free mice resulted in
impaired mucus detachment in the small intestine (Sch€utte
et al., 2014), we analyzed MUC2 staining and meprin b protein
levels in VilCreER;Adam10f/f mice (Tsai et al., 2014). These
tamoxifen-inducible ADAM10-deficient animals showed a
mucus layer that appeared to be similar to that of meprin b-defi-
cient mice (Figures 5A and 5B). However, it should be noted that,
in VilCreER;Adam10f/f mice, Notch signaling is abolished, lead-
ing to goblet cell hyperplasia (Tsai et al., 2014), whereas no dif-
ferences in goblet cell numbers were observed in meprin b-defi-
cient mice (Figures S4A and S4B). In contrast, VilCre;Adam17f/f
mice showed no evidence for mucus layer alteration (Figure 5C)
nor differences in the amount of specific intestinal cell types (Fig-
ure S4C), as shown previously (Feng et al., 2015). To further
analyze the influence of ADAM10/17 on meprin b-mediated
mucus detachment in the small intestine, we employed a murine
ex vivo tissue explant model (Gustafsson et al., 2012b). As
expected, mucus detachment was abrogated in Mep1b/ ex-
plants and could also be inhibited in WT tissue by applying the
meprin inhibitor actinonin (Sch€utte et al., 2014; Gustafsson
et al., 2012a; Ermund et al., 2015a, 2015b; Figure 5D). Interest-
ingly, impaired mucus detachment was also observed when ileal
explants from WT mice were incubated with the ADAM10/17 in-
hibitor GW but not upon incubation with the ADAM10-selective
inhibitor GI. However, both ADAM10 and ADAM17 are capable
of shedding the murine meprin b, as shown by co-expression
of mMeprin b with ADAM10/17 in ADAM10/17/ HEK293T
cells, which resulted in increased amounts of meprin b CTFs
(Figure S5). Thus, unlike the specific requirement for ADAM10
in human pro-meprin b shedding, both ADAM10 and ADAM17
can contribute to pro-meprin b shedding in the murine small
intestine.
In small intestinal organoids derived from meprin b-deficient
and WT control mice, no obvious phenotypic differences in
growth or morphology were observed (Figure 6A). Remarkably,
western blot analysis of organoid lysates fromWTmice revealed
only a single band for mMeprin b at approximately 130 kDa,
corresponding to its membrane-bound full-length form,
which was lacking in organoids isolated from Mep1b/ mice
(Figure 6B). By contrast, in isolated human small intestinal(D) Mucus thickness measurements were performed in WT (n = 4) andMep1b/
meprin inhibitor actinonin (n = 4), the dual ADAM10/17 inhibitor GW (n = 7), or the
analysis was assessed by Mann-Whitney test (*p < 0.05, **p < 0.01).
See also Figure S4.organoids, although immunoblotting revealed a major band at
approximately 120 kDa, corresponding to full-length meprin b,
an additional faint faster-migrating band suggestive of shed
hMeprin bwas detected (Figure 6C). These results provide addi-
tional evidence about the differences in shedding observed for
murine versus human meprin b and are in line with other studies
detecting mMeprin b predominantly in its membrane-bound but
not in its soluble form (Marchand et al., 1994; Gorbea et al., 1993;
Craig et al., 1987).
Similar to isolated murine organoids, germ-free mice also lack
shedmeprin b in the small intestine and showaMUC2phenotype
comparable with meprin b-deficient mice (Sch€utte et al., 2014).
These observations raised the possibility that pro-meprin b shed-
ding is triggeredby bacterial stimuli in vivo. To test this possibility,
we stimulated transfectedHEK293Tcellswith thebacterial endo-
toxins lipopolysaccharide (LPS) or lipoteichoic acid (LTA). LPS
from the outer membrane of Gram-negative bacteria is a known
stimulator of ADAM17 via activation by polo-like kinase-2
(PLK2) (Schwarz et al., 2014), whereas LTA from the cell wall of
Gram-positive bacteria stimulates ADAM10 activity via platelet
activation factor receptor (PAFR) (Lemjabbar and Basbaum,
2002). Upon LTA stimulation, increased amounts of shed
meprin b, associated with increased proteolytic activity of
trypsin-activated soluble meprin b, were detected in the cell su-
pernatant, which was not the case after LPS stimulation (Figures
6D–6F). Consistent with our previous results, ADAM10 was the
major sheddase of human pro-meprin b, which could be induced
by bacterial LTA in HEK293T cells (Figure 6G). A similar tendency
toward LTA-induced pro-meprin b shedding by ADAM10, but not
ADAM17, was observed in Colo320 cells (Figure S6).
Membrane-Bound Meprin b Is Activated by the
Pathogenic Gingipain Protease RgpB, Impairing Its
Shedding
Although interaction of meprin bwith MT-2 impairs ADAM-medi-
ated pro-meprin b shedding, and active solublemeprin bwas not
detected in any experiment, activation of membrane-bound
meprin bmight abrogate its shedding per se. Because LTA treat-
ment can induce ADAM-mediated pro-meprin b shedding, it
raised the possibility that host-microbiome interactions might
be involved in this shedding event. To determine whether patho-
genic bacteria can interrupt this regulatory mechanism, we
analyzed the isolated secreted bacterial protease Arg-gingipain
(RgpB) from P. gingivalis, which is well studied in periodontitis
but is also found to colonize and harm the gastrointestinal tract
(Nakajima et al., 2015). Importantly, RgpB can efficiently cleave
MUC2, disrupting the MUC2 polymeric network (van der Post
et al., 2013). In addition, RgpB exhibits a cleavage preference
for arginine in the P1 position (Chen et al., 1992; Potempa
et al., 1998), consistent with the already identified activation
site of hMeprin b at Arg61 (Ja¨ckle et al., 2015). To investigate
the effect of RgpB on pro-meprin b shedding, we stimulatedmouse ilea (n = 4). Ileal explants fromWTmice were apically incubated with the
ADAM10 inhibitor GI (n = 5). Data are presented as mean ± SEM, and statistical
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Figure 6. ADAM-Mediated Pro-meprin b Shedding Requires Stimulation by the Host Microbiome
(A) No morphological differences were observed in intestinal organoids isolated from meprin b-deficient mice or control animals. Scale bars, 200 mm.
(B) Immunoblotting of lysates from murine intestinal organoids.
(C) Immunoblotting of lysates from human intestinal organoids. The western blot was exposed in different intensities, marked by the dashed line.
(D) Meprin b-transfected HEK293T cells were stimulated with 50 mg/mL LTA or 1 mg/mL LPS. Proteins were detected by immunoblotting.
(E) Densitometric analysis of shed meprin b from three biological replicates as shown in (D).
(F) Quantification of meprin b activity in cell supernatants (trypsin-activated) from three biological replicates. Data are presented as mean ± SD, and statistical
analysis was assessed by one-way ANOVA followed by a Dunnett’s test (*p < 0.05).
(G) Model of LTA-induced ADAM10-mediated pro-meprin b shedding.
See also Figure S6.meprin bexpressing ADAM10/17/ HEK293T cells with
RgpB. Interestingly, soluble meprin b levels in supernatants of
ADAM10/17 co-expressing cells were decreased after RgpB
treatment (Figure 7A). To avoid the contribution of full-length me-
prin b release via microvesicles, cell supernatants were ultracen-
trifuged prior to analysis. Indeed, meprin b cell surface activity
confirmed the pathogenic protease RgpB to be a specific
activator of membrane-bound meprin b (Figure 7B). Here we
observed meprin b activity in cell supernatants of RgpB-treated
cells without previous trypsin activation, indicating that the gingi-
pain protease RgpB activates soluble pro-meprin b as well (Fig-
ure 7C). However, meprin b activity in cell supernatants could be
further increased upon trypsin treatment (Figure 7D). Decreased
protein levels of soluble meprin b together with reducedmeprin b2098 Cell Reports 21, 2090–2103, November 21, 2017activity in supernatants of RgpB-treated cells (Figures 7A and
7D) demonstrate that only inactive pro-meprin b is shed by
ADAM proteases. Furthermore, increasing concentrations of
RgpB could completely abolish ADAM-mediated pro-meprin b
shedding (Figures 7E and 7F), clearly demonstrating that
RgpB-mediated activation of membrane-bound meprin b blocks
ADAM-mediated pro-meprin b shedding.
In addition to its crucial role in mucus detachment under phys-
iological conditions, meprin b mRNA is downregulated in bi-
opsies of Crohn’s disease (CD) patients, implicating a loss of
meprin b function in IBD (Vazeille et al., 2011). To assess
changes in meprin b protein levels, we analyzed the amount of
membrane-bound meprin b in inflamed and non-inflamed ileal
biopsies derived from CD patients using an antibody specific
Figure 7. Meprin b Is Activated by the Pathogenic Protease RgpB
(A) ADAM10/17/ HEK293T cells were transfected with meprin b and incubated with the purified gingipain protease RgpB (100 nM). Proteins were analyzed by
immunoblotting.
(B) Cell surface activity of meprin b.
(C) Meprin b activity in ultracentrifuged cell supernatants.
(D) As in (C) but trypsin-activated. SD was calculated from two technical replicates.
(E and F) ADAM10/17/ HEK293T cells were co-transfected either with (E) ADAM10 and meprin b or (F) ADAM17 and meprin b and stimulated with RgpB in
different concentrations.
(G) Model of the regulation of meprin b shedding and activation in health and disease.for the C terminus of meprin b. Intriguingly, we observed a trend
toward increased activated, membrane-bound meprin b protein
levels in inflamed tissue samples compared with non-inflamed
tissue, suggesting that ADAM-dependent meprin b sheddingand mucus detachment are compromised in the inflamed state
(Figure S7).
In summary, we have identified a unique regulatory mecha-
nism of meprin b shedding and activation that most likely isCell Reports 21, 2090–2103, November 21, 2017 2099
regulated by specific host-microbiome interactions that could
directly influence themeprin b substrate repertoire andmodulate
mucus detachment (Figure 7G).
DISCUSSION
The biological function of meprin b strictly depends on its local-
ization at the cell surface or whether it is released by ectodomain
shedding. For example, membrane-bound meprin b sheds APP
at the b-secretase cleavage site, leading to the generation of am-
yloid-b peptides, which tend to aggregate in the brains of Alz-
heimer’s disease patients (Bien et al., 2012). However, this
b-secretase activity is completely abrogated for soluble meprin
b (Bien et al., 2012). In contrast, MUC2 cleavage in the small in-
testine is only achieved by soluble meprin b and is important for
proper mucus function (Sch€utte et al., 2014). Disturbed mucus
production and detachment lead to pathological conditions
such as cystic fibrosis (O’Sullivan and Freedman, 2009).
Here we demonstrate that only inactive pro-meprin b is shed
from the cell surface by ADAM proteases. We recently identified
MT-2 as a membrane-bound activator of meprin b (Ja¨ckle et al.,
2015), and we now show that ADAM-dependent pro-meprin b
shedding is completely abolished upon binding and activation
by MT-2. Moreover, in ADAM10/17/ HEK293T cells, meprin
b is secreted exclusively via microvesicles, eliminating the possi-
bility that other proteases can compensate for pro-meprin b
shedding in this cell line. It is conceivable that microvesicle
release is a protective mechanism to avoid an overload of active
meprin b at the cell surface. Indeed, in a mouse model of
renal injury in which an overload of active membrane-bound
meprin b has been reported, meprin b was found to be translo-
cated from the apical to the basolateral surface of renal cells,
leading to severe inflammation, increased leukocyte infiltration,
and stronger brush border disruption (Bylander et al., 2008).
Consistent with the idea that high levels of active membrane-
bound meprin bmight be detrimental and associated with path-
ological processes, we detectedmore active full-length meprin b
in inflamed ileal tissues derived from patients suffering from CD
than in non-inflamed tissue.
ADAMs and meprin b are highly expressed in epithelial cells of
the small intestine (Sterchi et al., 1988; Lottaz et al., 1999; Jones
et al., 2016), and soluble pro-meprin b can easily be activated
by secreted serine proteases such as pancreatic trypsin or kalli-
kreins (Gr€unberg et al., 1993). We already excluded the presence
of MT-2 in epithelial cells of the murine small intestine (Ja¨ckle
et al., 2015), which is a prerequisite for meprin b shedding,
because we now show that activation of membrane-bound me-
prin b by MT-2 completely prevents its shedding. Endogenous
meprin b shedding in Colo320 cells provided strong evidence
that ADAM10 is the constitutive sheddase of pro-meprin b. In
contrast, we observed abolished mucus detachment in ex vivo
mucus thickness measurements after applying the ADAM10/17
inhibitor GW but not upon incubation with the ADAM10-selective
inhibitor GI. However, no increase in MUC2 staining was
observed in Adam17f/f mice, as shown for meprin b-deficient
animals. Increased MUC2 staining in VilCreER;Adam10f/f mice
can rather be explained by the previously described hyperplasia
of goblet cells, which are the main source of MUC2 in the small2100 Cell Reports 21, 2090–2103, November 21, 2017intestine (Tsai et al., 2014). Thus, in the murine system, ADAM10
and ADAM17 most likely act redundantly on pro-meprin b shed-
ding. Analysis of ADAM10/17 double-deficient mice will show
whether there are other, not yet identified proteases involved in
pro-meprin b shedding as well.
Generation of an EGF-chimera in which the identified ADAM17
cleavage site for hMeprin b between amino acids Q595 and L598
(Hahn et al., 2003) was exchanged confirmed involvement of
different pro-meprin b sheddases in the murine versus the
human system. Although ADAM10 prefers shedding of human
pro-meprin b, ADAM17 was still able to shed chimeric
meprin b because it prefers cleavage N-terminal of valine
residues (Tucher et al., 2014). However, increased levels of
meprin b CTFs after co-expressing ADAM10/17 in ADAM10/
17/HEK cells confirmed ADAM-mediated shedding of
mMeprin b. Chimeric meprin b could not be activated by MT-2
but by other serine proteases, such as trypsin, using the same
activation site at position Arg61. We therefore hypothesize
that this exchanged motif in meprin b, which shows the
weakest sequence homology between human and murine
meprin b (Pischitzis et al., 1999), is essential for the interaction
with ADAM10 and MT-2. Competing for the same sequence
motif explains the full blockade of ADAM-mediated pro-
meprin b shedding upon binding to MT-2.
Germ-freemice lack shedmeprin b and exhibit a severeMUC2
phenotype (Sch€utte et al., 2014). Additionally, only a minimal
amount of meprin b was shed from intestinal organoids under
sterile culture conditions, suggesting that a bacterial trigger
may be required to induce meprin b shedding. We show that
the bacterial endotoxin LTA can induce ADAM10-dependent
pro-meprin b shedding in HEK293T cells and Colo320 cells.
These findings suggest that important host-microbiome interac-
tions of meprin b with commensal microbiota exist that regulate
meprin b shedding, which plays a crucial role in the homeostasis
of proper mucus function. Additionally, it was shown that soluble
shed meprin b diminishes colonization of adherent-invasive
E. coli in the small intestine by cleaving bacterial type 1 pili
(Vazeille et al., 2011). Conclusively, decreased levels of soluble
meprin b and increased amounts of active full-length meprin b
correlate with the severity of intestinal inflammatory diseases,
as we observed for inflamed and control human ileal biopsies
from CD patients.
On the other hand, analysis of knockout mice revealed that
meprin b expression on leukocytes of the intestinal lamina
propria exhibits pro-inflammatory activity in DSS-induced colitis
(Crisman et al., 2004; Banerjee et al., 2011). Under inflammatory
conditions, the meprin b expression pattern is shifted from
epithelial cells to leukocytes of the lamina propria, completely
changing its substrate repertoire and further stimulating the
pro-inflammatory function (Lottaz et al., 2007). The bivalent func-
tion of meprin b regarding pro- and anti-inflammatory properties
as well as its changes in localization and subsequent substrate
repertoire indicate the importance of regulating meprin b shed-
ding and activation. Most interestingly, we identified RgpB
from the pathogen P. gingivalis to specifically activate mem-
brane-bound hMeprin b, preventing its shedding.
Different isoforms of gingipain proteases exist in soluble and
membrane-bound forms (Potempa et al., 1995), which account
for 85% of proteolytic activity of P. gingivalis at the site of infec-
tion (de Diego et al., 2014). In a murine periodontitis model,
the secreted proteases Kgp and RgpB have been identified as
major virulence factors accounting for P. gingivalis pathogenicity
(Pathirana et al., 2007). Although P. gingivalis is rather known
from periodontitis, it was also detected in the ileum of mice after
oral administration (Arimatsu et al., 2014). Additionally, a positive
correlation between gingival and intestinal inflammation has
been observed (Figueredo et al., 2017), and increased abun-
dance of P. gingivalis has been reported in the feces of colorectal
cancer patients (Ahn et al., 2013; Vogtmann et al., 2016). Thus,
activation of membrane-bound meprin b by RgpB and conse-
quential loss of pro-meprin b shedding from the cell surface
might change the meprin b substrate repertoire in multiple tis-
sues, including the gastrointestinal tract. It is conceivable that
the bacterial pathogen P. gingivalis, through its secreted prote-
ase RgpB, activates membrane-bound meprin b, which leads
to a loss of pro-meprin b shedding and perturbations in mucus
integrity. Additionally, oral administration of P. gingivalis to
mice can lead to disturbed gut microbiota in the ileum, systemic
inflammation, and increased intestinal permeability (Nakajima
et al., 2015; Whiting et al., 2015). Microbial dysbiosis is also
characteristic for IBD associated with metabolic effects, mucus
disruption, and altered immunological response (Wlodarska
et al., 2015). Importantly, the direct effect of RgpB on MUC2
polymer disruption (van der Post et al., 2013), together with
its activating properties on membrane-bound meprin b, might
provide two distinct mechanisms to disrupt intestinal barrier
function and promote bacterial overgrowth. Significantly, RgpB
provides a proof of concept that activation of membrane-
bound hMeprin b prevents the production of soluble meprin b,
which functions as a mucus-detaching protease. In summary,
meprin b is a key mediator in the homeostasis of mucus integrity,
and its unique posttranslational regulation is required for proper
mucus function and protection against bacterial invasion.
EXPERIMENTAL PROCEDURES
Cell Culture Stimulation, Fluorogenic Peptide-based Activity Assay,
and Immunoblotting
Meprin b activity was measured in Colo320 cells or in transfected HEK293T
cells and ADAM10/17/ HEK293T cells by applying 50 mM of the highly spe-
cific quenched fluorogenic peptide substrate (7-methyloxycoumarin-4-yl)
acetyl (mca)-EDEDED-(K-ε-2,4-dinitrophenyl [dnp]). Additionally, cells were
stimulated with 1 mM IM (30 min) or 100 nM PMA (2 hr) or with 100 nM of the
purified cysteine protease RgpB from P. gingivalis (Sztukowska et al., 2012;
Veillard et al., 2015) to induce meprin b shedding. Remaining cell lysates
and supernatants were used for western blot analysis. Detailed methods
and all cDNA constructs or antibodies used can be found in the Supplemental
Experimental Procedures.
Mice, Tissue Collection, and Immunofluorescence Staining
All procedures performed in this study involving animals were in accordance
with the ethical standards set by the National Animal Care Committee of
Germany, approved by the Laboratory Animal Ethics Committee of the Univer-
sity of Gothenburg with certification number 73-2015, and in accordance with
the University Committee on the Use and Care of Animals at the University
of Colorado (B102614 (01)1E). 8- to 12-week-old male and female mice of
the following strains were used for histological sections: Mepb1b/ mice
(Norman et al., 2003) and the corresponding C57/BL6N WT mice, VilCre;
Adam17f/f mice, and Adam17f/f control mice (Feng et al., 2015) andtamoxifen-inducible intestinal epithelial cell-specific ADAM10-deficient mice
(VilCreER;Adam10f/f mice) (Tsai et al., 2014). Preparation and mounting of mu-
rine ileal explants for mucus thickness measurements were performed as
described previously (Gustafsson et al., 2012b). Murine small intestine was
additionally used to isolate primary organoid cultures as described previously
(VanDussen et al., 2015). Detailed methods and all antibodies used for immu-
nofluorescence microscopy of ileal tissue can be found in the Supplemental
Experimental Procedures.
Human Intestinal Biopsies
Human jejunal tissue biopsies were obtained from different adult donors (n = 3,
mean age 53.7 years, 2 males, 1 female) and used to isolate intestinal epithelial
cells for a primary human in vitromodel of the human small intestine (Schwein-
lin et al., 2016). Informed written consent was obtained beforehand, and the
study was approved by the institutional ethics committee on human research
of the JuliusMaximilians University W€urzburg (study approval number 182/10).
Human small intestinal enteroid cultures were generated from ileal pinch
biopsies obtained from patients undergoing endoscopy in accordance with
IRB protocol 14-2012 at the University of Colorado. Non-inflamed (n = 7)
and inflamed (n = 5) ileal biopsies from CD patients were analyzed for
meprin b protein levels. Patients gave written informed consent prior to colo-
noscopy for biopsy collection. Approval was granted by the ethics committee
of themedical faculty of Kiel University (B2321/98). Detailedmethods for tissue
preparation and analysis can be found in the Supplemental Experimental
Procedures.
Statistical Analysis
Western Blots were quantified with ImageJ, and the protein of interest was
normalized to actin levels. For the quantification of MUC2 on immunofluores-
cence images, a semi-automated method developed in-house was used.
Therefore, different tools of ImageMagick were deployed, and the same set-
tings were used for all images analyzed. The MUC2 signal was normalized
to nuclear DAPI staining. For activity assays, relative fluorescent units
(RFUs) were normalized to the control sample. All statistical analyseswere per-
formed with GraphPad Prism for unpaired Student’s t test or for one-way
ANOVA followed by a Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001). Values
were normalized and are shown asmean ± SD. For mucus attachment assays,
data are represented as mean ± SEM. Differences between groups were
assessed by Mann-Whitney test (*p < 0.05, **p < 0.01, ***p < 0.001).
Additional material and methods are available in the Supplemental Experi-
mental Procedures.
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